FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3033019192> ?p ?o ?g. }

• W3033019192 endingPage "983" @default.
• W3033019192 startingPage "983" @default.
• W3033019192 abstract "Background: Anemia is a common comorbidity in patients with rheumatoid arthritis (RA). Objectives: Assess whether low hemoglobin (Hb) identifies a subgroup of patients at increased risk of joint damage progression, and investigate whether sarilumab modulates this risk. Methods: The 52-week, double-blind, Phase 3 MOBILITY trial ( NCT01061736 ) in patients with active RA and inadequate response to methotrexate (n = 1197) demonstrated the tolerability and efficacy (clinical and radiographic) of subcutaneous sarilumab 150 and 200 mg every 2 weeks versus placebo, both in combination with methotrexate (MTX). In this post hoc analysis, baseline characteristics and radiographic outcomes in MOBILITY were analyzed by baseline Hb category (low or normal) according to World Health Organization criteria, with low Hb defined as <120 g/L for women and <130 g/L for men. Nominal P values are presented. Results: A total of 414 patients (35%) had low Hb at baseline. Patients with low Hb were more likely than patients with normal Hb to be female (86% vs 79%, respectively), Asian (14% vs 5%), younger (mean age 49 vs 51 years), and to have lower body weight (mean 69 vs 77 kg); all nominal P <0.01. Duration of RA, prior biologic use, rheumatoid factor positivity, and baseline tender and swollen joint counts were similar between patients with low and normal baseline Hb, but there was a nominally significant difference in C-reactive protein (mean 30.2 [SD 28.5] vs 17.3 [18.5] mg/L; P <0.0001). Patients with low Hb generally exhibited more joint damage progression over 52 weeks than patients with normal Hb (Table). In the sarilumab + MTX groups, joint damage progression was mitigated compared with placebo + MTX in patients with low Hb and in patients with normal Hb. Mean change from baseline in Hb at 52 weeks in the placebo + MTX, sarilumab 150 mg + MTX, and sarilumab 200 mg + MTX groups was +3.7 (SD 10.8), +14.7 (12.1), and +14.0 (10.5) g/L, respectively, in patients with low Hb at baseline, and –2.5 (9.9), +6.2 (9.3), and +8.0 (9.9) g/L in patients with normal Hb at baseline. Table. Mean change from baseline (SD) in radiographic measures of joint damage Placebo + MTX Sarilumab 150 mg + MTX Sarilumab 200 mg + MTX Low Hb (n = 140 ) Normal Hb (n = 258 ) Low Hb (n = 145 ) Normal Hb (n = 255 ) Low Hb (n = 129 ) Normal Hb (n = 270 ) mTSS 3.75 (9.00) 2.29 (6.98) 1.20*** (5.58) 0.73** (4.07) 0.60*** (4.13) 0.08*** (4.83) Joint space narrowing 1.52 (3.71) 1.22 (3.92) 0.79* (3.17) 0.30** (2.70) 0.50** (2.93) 0.06*** (3.33) Erosion score 2.24 (6.24) 1.07 (3.91) 0.41*** (3.18) 0.44* (2.05) 0.10*** (2.13) 0.02*** (2.19) Nominal P *<0.05, **<0.01, ***<0.001 versus placebo by rank ANCOVA model stratified by prior biologic use and region; mTSS, modified total Sharp score Conclusion: Overall, sarilumab slowed joint damage progression in patients with RA. Additionally, in those patients with low Hb, who may suffer greater damage than those with normal Hb, sarilumab also increased Hb. Acknowledgments: Study funding and medical writing support (Matt Lewis, PhD, of Adelphi Communications Ltd, Macclesfield, UK) were provided by Sanofi Genzyme (Cambridge, MA, USA) and Regeneron Pharmaceuticals, Inc. (Tarrytown, NY, USA) in accordance with Good Publication Practice (GPP3) guidelines. Disclosure of Interests: Gerd Rüdiger Burmester Consultant of: AbbVie Inc, Eli Lilly, Gilead, Janssen, Merck, Roche, Pfizer, and UCB Pharma, Speakers bureau: AbbVie Inc, Eli Lilly, Gilead, Janssen, Merck, Roche, Pfizer, and UCB Pharma, Jean-Pierre Morello Shareholder of: Regeneron Pharmaceuticals, Inc., Employee of: Regeneron Pharmaceuticals, Inc., Owen Hagino Shareholder of: Sanofi, Employee of: Sanofi, Amy Praestgaard Employee of: Sanofi Genzyme, Stefano Fiore Shareholder of: Sanofi, Employee of: Sanofi, Mark C. Genovese Grant/research support from: Abbvie, Eli Lilly and Company, EMD Merck Serono, Galapagos, Genentech/Roche, Gilead Sciences, Inc., GSK, Novartis, Pfizer Inc., RPharm, Sanofi Genzyme, Consultant of: Abbvie, Eli Lilly and Company, EMD Merck Serono, Genentech/Roche, Gilead Sciences, Inc., GSK, Novartis, RPharm, Sanofi Genzyme" @default.
• W3033019192 created "2020-06-12" @default.
• W3033019192 creator A5003223457 @default.
• W3033019192 creator A5003819213 @default.
• W3033019192 creator A5004289717 @default.
• W3033019192 creator A5016018012 @default.
• W3033019192 creator A5029342656 @default.
• W3033019192 creator A5076851275 @default.
• W3033019192 date "2020-06-01" @default.
• W3033019192 modified "2023-10-03" @default.
• W3033019192 title "SAT0100 ASSOCIATION BETWEEN LOW HEMOGLOBIN AND RADIOGRAPHIC PROGRESSION OVER 52 WEEKS IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS FROM A PHASE 3 TRIAL OF SARILUMAB" @default.
• W3033019192 doi "https://doi.org/10.1136/annrheumdis-2020-eular.2008" @default.
• W3033019192 hasPublicationYear "2020" @default.
• W3033019192 type Work @default.
• W3033019192 sameAs 3033019192 @default.
• W3033019192 citedByCount "1" @default.
• W3033019192 countsByYear W30330191922022 @default.
• W3033019192 crossrefType "journal-article" @default.
• W3033019192 hasAuthorship W3033019192A5003223457 @default.
• W3033019192 hasAuthorship W3033019192A5003819213 @default.
• W3033019192 hasAuthorship W3033019192A5004289717 @default.
• W3033019192 hasAuthorship W3033019192A5016018012 @default.
• W3033019192 hasAuthorship W3033019192A5029342656 @default.
• W3033019192 hasAuthorship W3033019192A5076851275 @default.
• W3033019192 hasConcept C126322002 @default.
• W3033019192 hasConcept C141071460 @default.
• W3033019192 hasConcept C142724271 @default.
• W3033019192 hasConcept C197934379 @default.
• W3033019192 hasConcept C204787440 @default.
• W3033019192 hasConcept C27081682 @default.
• W3033019192 hasConcept C2776232647 @default.
• W3033019192 hasConcept C2777575956 @default.
• W3033019192 hasConcept C2778248108 @default.
• W3033019192 hasConcept C2778375690 @default.
• W3033019192 hasConcept C2778917026 @default.
• W3033019192 hasConcept C2781059491 @default.
• W3033019192 hasConcept C67761136 @default.
• W3033019192 hasConcept C71924100 @default.
• W3033019192 hasConcept C90924648 @default.
• W3033019192 hasConceptScore W3033019192C126322002 @default.
• W3033019192 hasConceptScore W3033019192C141071460 @default.
• W3033019192 hasConceptScore W3033019192C142724271 @default.
• W3033019192 hasConceptScore W3033019192C197934379 @default.
• W3033019192 hasConceptScore W3033019192C204787440 @default.
• W3033019192 hasConceptScore W3033019192C27081682 @default.
• W3033019192 hasConceptScore W3033019192C2776232647 @default.
• W3033019192 hasConceptScore W3033019192C2777575956 @default.
• W3033019192 hasConceptScore W3033019192C2778248108 @default.
• W3033019192 hasConceptScore W3033019192C2778375690 @default.
• W3033019192 hasConceptScore W3033019192C2778917026 @default.
• W3033019192 hasConceptScore W3033019192C2781059491 @default.
• W3033019192 hasConceptScore W3033019192C67761136 @default.
• W3033019192 hasConceptScore W3033019192C71924100 @default.
• W3033019192 hasConceptScore W3033019192C90924648 @default.
• W3033019192 hasIssue "Suppl 1" @default.
• W3033019192 hasLocation W30330191921 @default.
• W3033019192 hasOpenAccess W3033019192 @default.
• W3033019192 hasPrimaryLocation W30330191921 @default.
• W3033019192 hasRelatedWork W2100063456 @default.
• W3033019192 hasRelatedWork W2114291971 @default.
• W3033019192 hasRelatedWork W2118084423 @default.
• W3033019192 hasRelatedWork W2133148194 @default.
• W3033019192 hasRelatedWork W2147606462 @default.
• W3033019192 hasRelatedWork W2414220780 @default.
• W3033019192 hasRelatedWork W2508614712 @default.
• W3033019192 hasRelatedWork W2783466784 @default.
• W3033019192 hasRelatedWork W4294301186 @default.
• W3033019192 hasRelatedWork W2185841895 @default.
• W3033019192 hasVolume "79" @default.
• W3033019192 isParatext "false" @default.
• W3033019192 isRetracted "false" @default.
• W3033019192 magId "3033019192" @default.
• W3033019192 workType "article" @default.